ConductScience.org, home

Paper750106

The clinical evaluation of analogues. I. The overall problem.

Carter SK. Cancer Chemother Pharmacol, 1978. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. The clinical evaluation of analogues. I. The overall problem. Papers, record 750106. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/750106

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The clinical evaluation of analogues. I. The overall problem.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.75
iCite
Revised in PubMed
2019-08-27
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Carter SKS K

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Drug EvaluationMajor topic
NeoplasmsMajor topic
Humans
Research Design

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1766582Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential.Adv Cancer Res1975https://conductscience.org/library/papers/766582PubMed
2804350Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.Cancer Res1975https://conductscience.org/library/papers/804350PubMed
3328137Clinical trials in cancer chemotherapy.Cancer1977https://conductscience.org/library/papers/328137PubMed
4373904Cancer chemotherapy as it approaches middle age.Cancer Chemother Pharmacol1978https://conductscience.org/library/papers/373904PubMed
5794496Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial.J Natl Cancer Inst1976https://conductscience.org/library/papers/794496PubMed
64534592Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy.Cancer Treat Rev1974https://conductscience.org/library/papers/4534592PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
7002528Cancer chemotherapy: new developments and changing concepts.Drugs1980https://conductscience.org/library/papers/7002528PubMed
2311167Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2311167PubMed
393427m-AMSA and PALA: two new agents in cancer chemotherapy.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/393427PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/750106

GET https://conductscience.org/api/papers/v1/750106/authors